UK – NICE hits Keytruda with ‘no’ for urothelial cancer

The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) locally advanced or metastatic urothelial carcinoma.

The rejection, which would have been for adults who have had platinum-containing chemotherapy, comes after a review of new evidence collected while the MSD blockbuster was available via the Cancer Drugs Fund.

NICE says that there is still uncertainty surrounding the long-term benefit of the second-line immunotherapy treatment in comparison with other options, meaning it is not a “cost-effective use of NHS resources at its current price.”

The organisation says that the drug will be withdrawn from the Cancer Drugs Fund once final guidance has been published, meaning that no new patients will be offered the treatment, although it will not affect those whose treatment was started before the final guidance was published…